Want to see ORIC full AI Analyst Report?
Top Page
Oric Pharmaceuticals
(NASDAQ:ORIC)
Select Model
Select Model
Rating:51Neutral
Price Target:
$10.50
▼(-13.22% Downside)
Action:Reiterated
Date:08/04/26
ORIC scores in the low-50s primarily due to weak operating fundamentals—no revenue, widening losses, and sizable ongoing cash burn—partly offset by a low-debt, well-capitalized balance sheet. Technicals are neutral-to-slightly supportive (positive MACD, neutral RSI, trading above key medium-term averages), while valuation is pressured by a negative P/E and no provided dividend yield. Corporate events are mildly positive on governance and flexibility but carry potential dilution considerations.
Positive Factors
Balance sheet strength
Very low leverage and roughly $381M of equity materially reduce default and refinancing risk for a clinical-stage biotech. This financial flexibility supports continued R&D and multi-year clinical programs, giving the company runway to advance trials without immediate revenue.
Negative Factors
No revenues; widening net losses
Absence of product revenue and expanding losses indicate the company remains pre-revenue and dependent on pipeline success. Persistent negative profitability limits internal funding capacity and raises execution risk if clinical outcomes or timelines slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low leverage and roughly $381M of equity materially reduce default and refinancing risk for a clinical-stage biotech. This financial flexibility supports continued R&D and multi-year clinical programs, giving the company runway to advance trials without immediate revenue.
Read all positive factors
Oric Pharmaceuticals (ORIC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.42B
Dividend YieldN/A
Average Volume (3M)1.65M
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue GrowthN/A
EPS Growth28.64%
CountryUS
Employees111
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.35
Shares Outstanding103,652,660
10 Day Avg. Volume1,549,507
30 Day Avg. Volume1,650,377
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-6.30
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$21.56Price Target Upside78.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.5
Revenue Forecast (FY)N/A
Oric Pharmaceuticals Business Overview & Revenue Model
Company Description
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage dr...
How the Company Makes Money
ORIC does not have recurring revenue from the sale of approved pharmaceutical products; as a clinical-stage biotech, it typically finances operations primarily through capital raising (e.g., issuing equity and other financing activities). Informat...
Oric Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -584.00K | -1.22M | -1.11M | -1.03M | 0.00 | 0.00 |
| EBITDA | -143.01M | -128.25M | -126.74M | -99.67M | -85.80M | -77.82M |
| Net Income | -140.35M | -129.47M | -127.85M | -100.70M | -89.12M | -78.72M |
Balance Sheet | ||||||
| Total Assets | 404.69M | 411.00M | 274.14M | 254.69M | 250.36M | 298.64M |
| Cash, Cash Equivalents and Short-Term Investments | 264.76M | 281.49M | 255.96M | 208.19M | 206.27M | 236.98M |
| Total Debt | 3.33M | 11.55M | 3.18M | 10.21M | 12.10M | 1.93M |
| Total Liabilities | 23.43M | 26.64M | 31.02M | 30.60M | 28.01M | 25.67M |
| Stockholders Equity | 381.26M | 384.36M | 243.12M | 224.09M | 222.35M | 272.98M |
Cash Flow | ||||||
| Free Cash Flow | -112.42M | -114.08M | -113.85M | -86.54M | -77.22M | -60.48M |
| Operating Cash Flow | -111.64M | -113.37M | -112.66M | -85.69M | -75.14M | -59.54M |
| Investing Cash Flow | -99.66M | -148.03M | 22.14M | -43.40M | -109.25M | 158.44M |
| Financing Cash Flow | 172.92M | 245.26M | 126.55M | 85.66M | 25.23M | 49.13M |
Oric Pharmaceuticals Technical Analysis
Positive
12.10
Price Trends
10.63
Positive
10.10
Positive
10.59
Positive
Market Momentum
0.91
Negative
68.26
Neutral
90.66
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORIC, the sentiment is Positive. The current price of 12.1 is below the 20-day moving average (MA) of 12.25, above the 50-day MA of 10.63, and above the 200-day MA of 10.59, indicating a bullish trend. The MACD of 0.91 indicates Negative momentum. The RSI at 68.26 is Neutral, neither overbought nor oversold. The STOCH value of 90.66 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORIC.
Oric Pharmaceuticals Risk Analysis
Oric Pharmaceuticals disclosed 98 risk factors in its most recent earnings report. Oric Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oric Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $10.29B | -28.33 | -34.15% | ― | -100.00% | -5.32% | |
66 Neutral | $8.98B | -53.14 | -24.32% | ― | ― | 28.51% | |
62 Neutral | $2.59B | -54.65 | -23.59% | ― | ― | 18.54% | |
54 Neutral | $841.64M | 78.24 | 3.50% | ― | 7.44% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.42B | -10.27 | -35.35% | ― | ― | 28.64% | |
43 Neutral | $574.96M | -2.81 | -188.27% | ― | -17.90% | 32.10% |
* Healthcare Sector Average
ORIC
Oric Pharmaceuticals
13.87
4.21
43.58%
SYRE
Spyre Therapeutics
103.63
86.68
511.39%
TRVI
Trevi Therapeutics
18.46
10.94
145.48%
PRAX
Praxis Precision Medicines
366.81
319.73
679.12%
PHAR
Pharming Group
11.72
0.07
0.60%
PRME
Prime Medicine, Inc.
3.09
-0.48
-13.45%
Oric Pharmaceuticals Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Oric Pharmaceuticals Expands Inducement Equity Incentive Plan
Positive
Jul 30, 2026
On July 28, 2026, ORIC Pharmaceuticals’ board approved an amended and restated 2022 Inducement Equity Incentive Plan, increasing the shares of common stock reserved for issuance to an aggregate of 3,350,000. The plan, adopted without stockho...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Oric Shareholders Approve Equity Plan, Governance Measures
Positive
Jun 22, 2026
On June 18, 2026, ORIC Pharmaceuticals’ shareholders approved an amended and restated 2020 Equity Incentive Plan that adjusts its evergreen feature, caps incentive stock option issuances at 10 million shares within the plan’s reserve, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.